Dr. Singh and colleagues comment on the low use of ezetimibe in participants enrolled in the BEIJERINCK (EvolocumaB Effect on LDL-C Lowering in SubJEcts with Human Immunodeficiency VirRus and INcreased Cardiovascular RisK) study ([1][1]). Our study was a multicenter, randomized, double-blind,

中文翻译：

---

回复

Singh 博士及其同事评论了在 BEIJERINCK（EvolocumaB 对人类免疫缺陷病毒和心血管风险增加的受试者中降低 LDL-C 的影响）研究（[1][1]）的参与者中依泽替米贝的低使用率。我们的研究是一项多中心、随机、双盲、